Blog

Discover our latest NDD’s results at the NEUROSCIENCE 2024 in Chicago

📌ETAP-Lab’s team will attend the upcoming NEUROSCIENCE 2024 from Saturday, October 5 to Wednesday, October 9, in Chicago (IL, USA), in McCormick Place Convention Center.

That meeting is the World’s Largest Neuroscience Conference, organized by the Society For Neuroscience (SFN), and with an exciting programming for the scientists coming from around the world!

 

ETAP-Lab will unveil two posters on original preclinical results about in vitro and in vivo assays on Alzheimer’s disease.

 

📅Let’s meet our scientists during the poster sessions

 

  • Nicolas Violle, CEO and expert in neuroscience, will present the poster #PSTR013.14 – Towards new relevant neuroinflammation models using oligomers involved in Alzheimer’s disease for target validation and drug testing. Poster presentation on Day 1 Sat., Oct. 5, 2024 from 2 p.m. to 3 p.m.

 

  • Julie Colin, Preclinical Project Manager in Neuroscience, will present collaborative results with our partner NETRI, also exhibiting in the congress – with the poster #PSTR387.08 – Brain-on-chip technology and high-content analysis system to improve and accelerate preclinical Alzheimer’s disease drug research. Poster presentation on  last Day, Wed., Oct. 9, 2024 from 11 a.m. to noon

 

🧠Our Neurological models, tailored to your challenges.

 

Would you like to empower your neurological drug development through preclinical studies ? You need to know how to test the efficacy of your molecules and your proof of concept?  You need to mimic the pathological features of NDD’s?

 

At ETAP-Lab we can advise with our relevant and translatable in vitro and in vivo models. We have developed a wide range of neurodegenerative diseases models (Alzheimer and Parkinson), as well as stroke models​ and in vivo models of young & aged rodents​ in psychopharmacology!

 

We also propose novel in vitro Brain-on-chip models that are developed in BIO-DIAMOND Project, a collaborative project with NETRI aiming at accelerating the time-to-market of drug candidates in the « discovery » and « pre-clinical » phases in the fields of Alzheimer’s, Parkinson’s and Amyotrophic Lateral Sclerosis (ALS).

France 2030 supports « Innovations in biotherapies and bioproduction » by selecting the NETRI and ETAP-Lab industrial consortium. Winners of the « Innovations in biotherapies and bioproduction » call for projects, financed by the government as part of France 2030, NETRI and ETAP-Lab have launched their BIO-DIAMOND project in 2023.

More information about the project advances here: https://netri.com/biodiamond/

 

More to discover:

Related Posts